With U.S Approval, EUSA Set To Prove Value of Transatlantic Spec Pharma Model – And Orphan Focus
This article was originally published in The Pink Sheet Daily
U.S approval of orphan drug Erwinase puts specialty pharma firm EUSA on new growth trajectory, showing the value of its strategy to build a transatlantic infrastructure for niche products – and transitioning it from a commercially-focused to a development-capable organization.
You may also be interested in...
Jazz Enters Oncology Market With EUSA Acquisition
Jazz strays away from its CNS focus with a $700 million acquisition of EUSA Pharma, adding the specialty pharma’s oncology product to its portfolio.
EUSA Wins U.S. Approval of Erwinaze; Shipping To Start Week Of Nov. 20
Eusa hopes the approval will help cement its efforts in the U.S., where it has been trying to build a strong presence for several years.
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?